D. Schadendorf

发表

Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.

J. Utikal, C. Berking, D. Schadendorf, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunotherapy in melanoma: Recent advances and future directions.

D. Schadendorf, B. Schilling, C. Franklin, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Glutathione and related enzymes in tumor progression and metastases of human melanoma.

D. Schadendorf, B. Czarnetzki, K. Jurgovsky, 1995, The Journal of investigative dermatology.

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

Monika S. Kowalczyk, A. Regev, P. Sorger, 2018, Cell.

Fatal swelling of the groin – Clear cell sarcoma: a rare but important differential diagnosis to malignant melanoma

D. Schadendorf, A. Roesch, A. Schulz, 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.

J. Utikal, C. Berking, D. Schadendorf, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Reply to the letters to the editor 'Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by Diwakar et al.

D. Schadendorf, B. Schilling, W. Sondermann, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.

A. Enk, D. Schadendorf, R. Dummer, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients.

C. Berking, D. Schadendorf, H. Eich, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG

M. Weichenthal, A. Hauschild, S. Haferkamp, 2023, Journal for ImmunoTherapy of Cancer.

Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety

R Hofmann-Wellenhof, R. Hofmann-Wellenhof, J. Paoli, 2014, The British journal of dermatology.

Advances and perspectives in immunotherapy of melanoma.

D. Schadendorf, E. Livingstone, L. Zimmer, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.

Joshua M. Stuart, Richard A. Moore, Lisle E. Mose, 2017, Cancer cell.

Melanoma tumour markers S100B and MIA: evaluation of stability in serum and blood upon storage and processing

D. Schadendorf, A. Sucker, U. Hofmann, 2001, The British journal of dermatology.

Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.

D. Schadendorf, Y. Sun, A. Paschen, 2000, Immunology letters.

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome

D. Schadendorf, H. Kurzen, R. Dummer, 2010, British Journal of Cancer.

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

D. Mallardo, E. Simeone, P. Lorigan, 2023, Journal of Translational Medicine.

Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.

J. Homsi, N. Khushalani, P. Swiecicki, 2023, The Lancet. Oncology.

Bupropion and generalized acute urticaria: a further case

N. Flanagan, A. Alexandroff, W. Loo, 2003, The British journal of dermatology.

Actual practice of melanoma follow‐up and treatment in Germany: results of a prospective, longitudinal cohort study

A. Hauschild, D. Schadendorf, K. Kähler, 2015, The British journal of dermatology.

Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.

J. Utikal, D. Schadendorf, B. Schilling, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy.

C. Gebhardt, I. Heidrich, Glenn Geidel, 2024, European journal of cancer.

Association between endothelin receptor B nonsynonymous variants and melanoma risk.

D. Schadendorf, S. Ugurel, K. Hemminki, 2006 .

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.

A. Sucker, F. Meier, A. Paschen, 2024, European journal of cancer.

Analysis of SDHD promoter mutations in various types of melanoma

W. Sondermann, A. Sucker, S. Horn, 2015, Oncotarget.

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

C. Berking, A. Hauschild, D. Schadendorf, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Early versus late response to PD-1-based immunotherapy in metastatic melanoma.

P. Jansen, A. Sucker, B. Hellwig, 2024, European journal of cancer.

Elevated MIA serum levels are of relevance for management of metastasized malignant melanomas: results of a German multicenter study.

A. Hauschild, D. Schadendorf, W. Stolz, 2000, Journal of Investigative Dermatology.

Serological detection of cutaneous T-cell lymphoma-associated antigens.

D. Schadendorf, R. Dummer, S. Eichmüller, 2001, Proceedings of the National Academy of Sciences of the United States of America.

The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.

K. Kähler, P. Ascierto, J. Wolchok, 2023, European journal of cancer.

Immunotherapy of distant metastatic disease

A. Hauschild, D. Schadendorf, A. Eggermont, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.